摘要
目的探讨吉西他滨联合顺铂治疗晚期非小细胞肺(NSCLC)的疗效及毒性。方法对26例晚期非小细胞肺癌患者予以顺铂80mg/m2,VD,第1天,吉西他滨800～1000/m2,VD,第1、8天,21d为一个周期,完成3个周期后评价疗效。结果全组总有效率为38.5%,其中鳞癌为40%,腺癌为36.4%,中位生存期12.1个月,1年生存率为41%。主要毒性反应为骨髓抑制和恶心呕吐,绝大多数患者可以耐受良好。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌是安全、有效的化疗方案,可延长患者生存存期,毒性反应可以耐受。
Objective To study the efficacy and toxicities of Geracitabine and Cisplatin on the treatment of advanced non - small cell lung cancer （NSCLC）. Methods There were 26 cases of advanced NSCLC patients who were treated with Cisplatin 80mg/m2 by intravenous infusion on the 1 st day, and Geracitabine 800 -1000mg/m2 by intravenous infusion on the 1 st and 8th days every 21 days. After 3 cycles the efficacy was valuated. Results： The overall response rate was 38.5% / 10eases partial response. The response was 40% for squamous eareinoma, 36.4% for adenouscareinoma. The median survival time was 12. 1 months. The 1-year surviv＇,d rate was 41%. The main toxieities were myelosuppression and nausea and vomiting. Asmost all the patients could tolerate the side effect. Conclusion Combination of gemeitabine and cisplatin is effective and were tolerated in the treatment of advanced NSCLC. The regimen also can prolong the survival time in some patients.
出处
《临床肺科杂志》
2008年第3期315-316,共2页
Journal of Clinical Pulmonary Medicine
关键词
晚期非小细胞肺癌
古西他滨
顺铂
联合化疗
Non-small cell lung cancer
gemcitabine
cisplatin
combined chemotherapy
